The prevalence of AR at a college campus was 58.5%. The presence of rhinitis symptoms was the highest predictor of the presence of AR, with 67.7% having subsequent positive SPT. Students with AR had poorer scores in every dimension of QoL as defined by the Rcq-36 when compared to their non-AR counterparts. Educational performances among the 2 groups were unaffected.

No abstract

No abstract

RATIONALE: Real-world data from a diverse sample of allergists/ immunologists were collected to better understand preferred terminology utilized in oral immunotherapy (OIT), especially when communicating with patients. METHODS: An online, self-administered survey was fielded to U.S. allergists/immunologists (12/28/2017-1/27/2018). Eligibility criteria included: completed training > _5 years ago; spent >20% of time in direct patient care; and managed > _50 patients with food allergy. Responses were stratified by whether physicians treated patients with OIT in the past year (OIT and non-OIT users). RESULTS: 101 allergists/immunologists participated (OIT users n548; non-OIT users n553). OIT users were more likely to be from a hospital/ academic-based clinic compared to non-OIT users (34% vs. 9%); while non-OIT users were more likely to be in a private practice or other outpatient clinic compared to OIT users (91% vs. 56%). ''Reactive dose'' during oral food challenge (OFC) was defined as the dose when symptoms occur (69.4%; 61.2%, respectively), but also as the lowest dose (8.2%; 20.4%) or cumulative dose (14.3%; 6.1%) when symptoms occur. ''Tolerated dose'' was defined as highest dose tolerated without symptoms (20.4%; 42.3%), the dose when no symptoms occur (36.7%; 23.1%), or as cumulative tolerated dose without symptoms (16.3%; 5.8%). Overall, 81% agreed that ''tolerated dose'' was most clinically meaningful. The majority (83.3%; 92.4%) felt stronger consensus among clinicians regarding OIT terminology would be extremely/very useful. CONCLUSIONS: While variability in definitions for OIT terminology was evident, both OIT and non-OIT users agreed that ''tolerated dose'' was the most clinically meaningful for patients to know, and that consensus in OIT terminology is needed.